Abcuro
Steven A. Greenberg, M.D., M.S. is a founder of Abcuro and is the Chief Scientific Advisor. Steven is a clinical neurologist at Brigham and Women’s Hospital and a Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics, including co-inventing a therapeutic monoclonal antibody for dermatomyositis currently in phase 2 studies. He has authored over 100 publications and served as Principal Investigator for multiple clinical trials, and is the founder of the non-profit research organization, the Inclusion Body Myositis Foundation. Steven received an A.B. degree in Mathematics from Princeton University, an M.S. degree in Medical Informatics from MIT, and an M.D. degree from Harvard Medical School through the Harvard-MIT Health Science and Technology Program.
This person is not in the org chart
This person is not in any teams
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.